Complete Filing Data
Acumen Pharmaceuticals, Inc. reported Stockholders Equity of $70.43 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Acumen Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Research And Development Expense | $104.9M | $93.8M | $42.3M | $32.4M | $12.3M | $8.0M |
| Operating Income Loss | -$123.8M | -$114.0M | -$61.1M | -$45.2M | -$19.6M | -$7.9M |
| Operating Expenses | $123.8M | $114.0M | $61.1M | $45.2M | $19.6M | $9.3M |
| Net Income Loss | -$121.3M | -$102.3M | -$52.4M | -$42.9M | -$100.6M | -$7.3M |
| General And Administrative Expense | $18.9M | $20.2M | $18.8M | $12.9M | $7.3M | $1.4M |
| Nonoperating Income Expense | $2.5M | $11.7M | $8.8M | $2.4M | -$81.0M | $587.0K |
| Other Nonoperating Income Expense | -$266.0K | -$151.0K | -$83.0K | -$11.0K | $51.0K | |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $131.0K | -$360.0K | $1.1M | -$520.0K | -$231.0K | |
| Comprehensive Income Net Of Tax | -$121.2M | -$102.7M | -$51.3M | -$43.4M | -$100.8M | |
| Interest Income Expense Nonoperating Net | $2.4M | $84.0K | $1.0K | |||
| Income Taxes Paid Net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense Nonoperating | $4.2M | $4.1M | $581.0K | |||
| Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | $59.0K | $97.0K | $11.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research And Development Expense | $22.0M | $37.1M | $25.3M | $27.2M | $19.5M | $12.4M | $11.2M | $9.1M | $8.7M | $8.3M | $7.3M | $6.0M | $1.8M | $2.3M | $2.6M | $3.0M | $1.9M |
| Operating Income Loss | -$26.5M | -$41.8M | -$30.4M | -$32.3M | -$24.4M | -$17.8M | -$16.0M | -$13.5M | -$13.1M | -$11.4M | -$10.4M | -$9.2M | -$3.9M | -$3.4M | -$3.8M | -$2.5M | -$2.0M |
| Operating Expenses | $26.5M | $41.8M | $30.4M | $32.3M | $24.4M | $17.8M | $16.0M | $13.5M | $13.1M | $11.4M | $10.4M | $9.2M | $3.9M | $3.4M | $3.8M | $3.2M | $2.2M |
| Net Income Loss | -$26.5M | -$41.0M | -$28.8M | -$29.8M | -$20.5M | -$14.9M | -$13.0M | -$11.6M | -$11.3M | -$10.7M | -$10.2M | -$9.1M | -$3.9M | -$61.4M | -$27.0M | -$2.5M | -$2.0M |
| General And Administrative Expense | $4.5M | $4.6M | $5.1M | $5.0M | $4.8M | $5.3M | $4.9M | $4.3M | $4.4M | $3.1M | $3.1M | $3.2M | $2.1M | $1.2M | $1.2M | $226.0K | $259.0K |
| Nonoperating Income Expense | $62.0K | $800.0K | $1.6M | $2.5M | $3.8M | $2.9M | $3.1M | $1.9M | $1.8M | $661.0K | $260.0K | $77.0K | $33.0K | -$57.9M | -$23.2M | ||
| Other Nonoperating Income Expense | -$69.0K | -$129.0K | -$64.0K | $33.0K | -$68.0K | -$54.0K | -$42.0K | -$16.0K | -$4.0K | -$2.0K | $0.00 | $1.0K | $19.0K | $19.0K | $9.0K | ||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $86.0K | $8.0K | $63.0K | $682.0K | -$20.0K | -$456.0K | $137.0K | -$122.0K | $227.0K | $0.00 | -$151.0K | -$583.0K | -$28.0K | ||||
| Comprehensive Income Net Of Tax | -$26.4M | -$40.9M | -$28.7M | -$29.1M | -$20.6M | -$15.3M | -$12.8M | -$11.7M | -$11.1M | -$10.7M | -$10.3M | -$9.7M | -$3.9M | -$2.5M | |||
| Interest Income Expense Nonoperating Net | $3.1M | $1.9M | $1.8M | $663.0K | $260.0K | $76.0K | $14.0K | $4.0K | $4.0K | ||||||||
| Income Taxes Paid Net | $0.00 | $0.00 | $0.00 | ||||||||||||||
| Interest Expense Nonoperating | $1.1M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $0.00 | $0.00 | |||||||||
| Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | $3.0K | $2.0K | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $70.4M | $181.8M | $267.0M | $188.8M | $225.2M | -$18.6M | -$11.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $54.2M | $35.9M | $67.1M | $130.1M | $122.2M | $43.8M | |
| Retained Earnings Accumulated Deficit | -$446.5M | -$325.1M | -$222.8M | -$170.4M | -$127.6M | -$27.0M | |
| Prepaid Expense And Other Assets Current | $5.4M | $6.7M | $3.1M | $2.7M | $4.4M | $543.0K | |
| Liabilities And Stockholders Equity | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M | $44.4M | |
| Liabilities | $52.4M | $57.2M | $43.2M | $7.8M | $5.1M | $6.4M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $18.4M | -$31.3M | -$63.0M | $7.9M | $78.4M | $37.2M | |
| Cash And Cash Equivalents At Carrying Value | $54.0M | $35.6M | $66.9M | $130.1M | $43.8M | $6.6M | |
| Assets Current | $122.3M | $178.3M | $246.6M | $180.3M | $198.7M | $44.4M | |
| Assets | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M | $44.4M | |
| Accounts Payable Current | $554.0K | $5.6M | $1.4M | $1.6M | $1.1M | $531.0K | |
| Other Assets Noncurrent | $350.0K | $486.0K | $724.0K | $151.0K | $14.0K | ||
| Marketable Securities Current | $62.9M | $135.9M | $176.6M | $47.5M | $72.1M | ||
| Common Stock Value | $6.0K | $6.0K | $6.0K | $4.0K | $4.0K | ||
| Marketable Securities Noncurrent | $0.00 | $60.0M | $62.6M | $15.8M | $31.6M | ||
| Liabilities Current | $30.0M | $27.6M | $13.0M | $7.8M | $5.1M | ||
| Accretion Amortization Of Discounts And Premiums Investments | $809.0K | $5.0M | $3.1M | -$487.0K | -$155.0K | ||
| Operating Lease Right Of Use Asset Amortization Expense | $126.0K | $115.0K | $123.0K | $137.0K | $0.00 | ||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Accrued Clinical Trial Expenses Current | $10.6M | $15.3M | $4.4M | $2.7M | $147.0K | ||
| Property Plant And Equipment Net | $36.0K | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $83.0K | -$48.0K | $312.0K | -$751.0K | |||
| Operating Lease Right Of Use Asset | $105.0K | $0.00 | |||||
| Accrued Liabilities Current | $10.1M | $6.6M | $6.4M | $3.4M | |||
| Operating Lease Liability Current | $105.0K | $0.00 | |||||
| Long Term Debt | $22.4M | $29.4M | $29.9M | $0.00 | |||
| Finance Lease Principal Payments | $0.00 | $739.0K | $0.00 | ||||
| Restricted Cash Noncurrent | $231.0K | $232.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $93.2M | $117.1M | $155.5M | $217.2M | $243.9M | $262.0M | $280.3M | $168.9M | $179.1M | $196.7M | $206.5M | $216.1M | $233.4M | -$106.1M | -$45.5M | -$17.9M | -$15.4M | -$13.4M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $47.1M | $37.0M | $30.4M | $33.4M | $68.2M | $47.2M | $95.1M | $77.2M | $78.0M | $157.5M | $111.1M | $108.8M | $135.8M | $68.8M | $41.4M | |||||||
| Retained Earnings Accumulated Deficit | -$421.3M | -$394.9M | -$353.9M | -$288.0M | -$258.2M | -$237.7M | -$206.3M | -$193.3M | -$181.7M | -$157.6M | -$146.9M | -$136.7M | -$119.2M | -$115.3M | ||||||||
| Prepaid Expense And Other Assets Current | $5.5M | $5.0M | $5.8M | $7.3M | $6.4M | $3.3M | $3.2M | $4.7M | $3.6M | $2.4M | $1.1M | $3.0M | $4.8M | $1.7M | ||||||||
| Liabilities And Stockholders Equity | $142.2M | $171.9M | $204.5M | $267.0M | $288.9M | $301.0M | $286.4M | $177.4M | $187.9M | $203.3M | $211.7M | $220.1M | $234.8M | $72.9M | ||||||||
| Liabilities | $49.0M | $54.8M | $49.0M | $49.8M | $45.0M | $38.9M | $6.1M | $8.5M | $8.8M | $6.6M | $5.2M | $4.0M | $1.5M | $4.5M | ||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$5.5M | -$20.0M | -$52.1M | -$13.4M | -$2.4M | |||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | $46.8M | $36.8M | $30.2M | $33.2M | $68.0M | $46.9M | $94.9M | $157.5M | $111.1M | $108.8M | $122.2M | $135.8M | $68.8M | $2.0M | $3.2M | |||||||
| Assets Current | $132.2M | $148.4M | $154.9M | $207.6M | $266.9M | $255.8M | $218.6M | $149.5M | $144.0M | $202.6M | $191.1M | $192.1M | $204.9M | $70.6M | ||||||||
| Assets | $142.2M | $171.9M | $204.5M | $267.0M | $288.9M | $301.0M | $286.4M | $177.4M | $187.9M | $203.3M | $211.7M | $220.1M | $234.8M | $72.9M | ||||||||
| Accounts Payable Current | $682.0K | $2.1M | $1.1M | $2.3M | $4.2M | $3.1M | $1.4M | $2.0M | $762.0K | $2.1M | $1.7M | $1.2M | $382.0K | $2.9M | ||||||||
| Other Assets Noncurrent | $393.0K | $464.0K | $504.0K | $170.0K | $425.0K | $324.0K | $189.0K | $208.0K | $195.0K | $92.0K | $106.0K | $79.0K | $13.0K | $13.0K | $0.00 | |||||||
| Marketable Securities Current | $79.8M | $106.6M | $119.0M | $167.2M | $192.5M | $205.6M | $120.5M | $67.6M | $62.4M | $42.7M | $78.8M | $80.3M | $64.2M | |||||||||
| Common Stock Value | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |||||||||
| Marketable Securities Noncurrent | $9.4M | $22.8M | $48.8M | $58.6M | $20.9M | $44.1M | $67.3M | $27.3M | $43.4M | $20.0M | $27.7M | $29.9M | ||||||||||
| Liabilities Current | $22.0M | $24.9M | $19.3M | $19.9M | $15.4M | $8.5M | $6.1M | $8.5M | $8.8M | $6.6M | $5.1M | $3.9M | ||||||||||
| Accretion Amortization Of Discounts And Premiums Investments | $588.0K | $1.8M | $334.0K | -$216.0K | ||||||||||||||||||
| Operating Lease Right Of Use Asset Amortization Expense | $30.0K | $28.0K | $38.0K | $33.0K | ||||||||||||||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||
| Accrued Clinical Trial Expenses Current | $9.9M | $11.1M | $11.5M | $12.5M | $7.0M | $2.4M | $1.6M | $4.1M | $5.2M | |||||||||||||
| Property Plant And Equipment Net | $89.0K | $105.0K | $117.0K | $122.0K | $123.0K | $136.0K | $151.0K | $165.0K | $142.0K | $113.0K | $51.0K | $13.0K | $6.0K | |||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $109.0K | $23.0K | $15.0K | $518.0K | -$164.0K | -$144.0K | -$509.0K | -$646.0K | -$28.0K | |||||||||||||
| Operating Lease Right Of Use Asset | $296.0K | $325.0K | $353.0K | $381.0K | $2.0K | $29.0K | $67.0K | $133.0K | $167.0K | $201.0K | ||||||||||||
| Accrued Liabilities Current | $7.8M | $11.7M | $6.7M | $4.9M | $4.0M | $2.9M | $3.2M | $2.4M | ||||||||||||||
| Operating Lease Liability Current | $129.0K | $125.0K | $121.0K | $110.0K | $2.0K | $29.0K | $67.0K | $133.0K | $142.0K | $139.0K | ||||||||||||
| Long Term Debt | $27.1M | $29.9M | $29.5M | $29.7M | $29.4M | $30.2M | ||||||||||||||||
| Finance Lease Principal Payments | $0.00 | $0.00 | $739.0K | $0.00 | $0.00 | |||||||||||||||||
| Restricted Cash Noncurrent | $232.0K | $232.0K | $232.0K | $236.0K | $235.0K | $234.0K | $233.0K | $189.0K | $0.00 | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $9.9M | $9.6M | $6.1M | $3.1M | $922.0K | $154.0K |
| Net Cash Provided By Used In Operating Activities | -$115.5M | -$86.2M | -$43.1M | -$35.2M | -$18.0M | -$7.5M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.4M | $3.7M | $369.0K | -$1.7M | $3.9M | -$53.0K |
| Increase Decrease In Other Operating Assets | -$40.0K | -$74.0K | $70.0K | $137.0K | $14.0K | -$144.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $3.3M | $32.0K | $2.9M | -$562.0K | $3.5M | -$119.0K |
| Increase Decrease In Accounts Payable | -$5.1M | $4.3M | -$261.0K | $552.0K | $557.0K | $308.0K |
| Payments To Acquire Productive Assets | $88.0K | $16.0K | $21.0K | $161.0K | $40.0K | |
| Net Cash Provided By Used In Investing Activities | $133.9M | $48.0M | -$171.7M | $39.2M | -$104.1M | |
| Payments To Acquire Marketable Securities | $38.1M | $170.7M | $250.6M | $41.5M | $104.1M | |
| Net Cash Provided By Used In Financing Activities | -$34.0K | $6.9M | $151.8M | $3.9M | $200.5M | $44.7M |
| Proceeds From Sale And Maturity Of Marketable Securities | $172.1M | $218.8M | $79.0M | $80.9M | $0.00 | |
| Increase Decrease In Accrued Clinical Trial Expenses | -$4.7M | $11.0M | $1.7M | $2.6M | $147.0K | |
| Proceeds From Stock Options Exercised | $39.0K | $0.00 | $325.0K | $115.0K | $15.0K | |
| Proceeds From Issuance Of Common Stock | $0.00 | $7.9M | $121.9M | $3.8M | $168.6M | |
| Payments For Deferred Offering Costs | $0.00 | $230.0K | $0.00 | |||
| Increase Decrease In Operating Lease Liability | -$110.0K | -$137.0K | $0.00 | |||
| Increase Decrease In Finance Lease Liability | $0.00 | -$23.0K | $17.0K | $0.00 | ||
| Payments Related To Tax Withholding For Share Based Compensation | $73.0K | $41.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $2.5M | $2.5M | $1.4M | $618.0K | $126.0K |
| Net Cash Provided By Used In Operating Activities | -$34.1M | -$17.9M | -$10.2M | -$8.3M | -$2.4M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$950.0K | $226.0K | $899.0K | -$1.4M | $44.0K |
| Increase Decrease In Other Operating Assets | -$16.0K | -$35.0K | $44.0K | $65.0K | $13.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $60.0K | -$3.5M | -$603.0K | -$1.8M | $954.0K |
| Increase Decrease In Accounts Payable | -$4.6M | $1.7M | -$878.0K | $121.0K | $387.0K |
| Payments To Acquire Productive Assets | $79.0K | $11.0K | $0.00 | $9.0K | |
| Net Cash Provided By Used In Investing Activities | $28.7M | -$9.2M | -$41.9M | -$5.1M | |
| Payments To Acquire Marketable Securities | $35.0M | $45.3M | $52.1M | $9.1M | |
| Net Cash Provided By Used In Financing Activities | -$36.0K | $7.1M | $0.00 | ||
| Proceeds From Sale And Maturity Of Marketable Securities | $63.8M | $36.1M | $10.2M | $4.0M | |
| Increase Decrease In Accrued Clinical Trial Expenses | -$3.8M | -$2.0M | $2.5M | $281.0K | |
| Proceeds From Stock Options Exercised | $37.0K | $0.00 | |||
| Proceeds From Issuance Of Common Stock | $0.00 | $7.9M | $0.00 | ||
| Payments For Deferred Offering Costs | $0.00 | $60.0K | $0.00 | ||
| Increase Decrease In Operating Lease Liability | -$21.0K | -$38.0K | -$32.0K | ||
| Increase Decrease In Finance Lease Liability | $0.00 | -$23.0K | $0.00 | ||
| Payments Related To Tax Withholding For Share Based Compensation | $73.0K | $32.0K | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | -$17.48 |
| Weighted Average Number Of Shares Outstanding Basic | 60.6M | 60.0M | 48.6M | 40.6M | 20.1M | |
| Weighted Average Number Of Diluted Shares Outstanding | 60.6M | 60.0M | 48.6M | 40.6M | 20.1M | |
| Earnings Per Share Basic | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-5.02 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 50.5M |
| Common Stock Shares Outstanding | 60.6M | 60.1M | 57.9M | 41.0M | 40.5M | 419.1K |
| Common Stock Shares Issued | 60.6M | 60.1M | 57.9M | 41.0M | 40.5M | 419.1K |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.44 | -$0.68 | -$0.48 | -$0.50 | -$0.34 | -$0.25 | -$0.24 | -$0.28 | -$0.28 | -$0.26 | -$0.25 | -$0.23 | -$0.10 | -$141.93 | -$64.41 | -$5.94 | -$4.86 |
| Weighted Average Number Of Shares Outstanding Basic | 60.6M | 60.6M | 60.5M | 60.1M | 60.1M | 59.8M | 54.2M | 41.0M | 41.0M | 40.5M | 40.5M | 40.5M | 38.3M | 432.3K | |||
| Weighted Average Number Of Diluted Shares Outstanding | 60.6M | 60.6M | 60.5M | 60.1M | 60.1M | 59.8M | 54.2M | 41.0M | 41.0M | 40.5M | 40.5M | 40.5M | 38.3M | 432.3K | |||
| Earnings Per Share Basic | $-0.44 | $-0.68 | $-0.48 | $-0.50 | $-0.34 | $-0.25 | $-0.24 | $-0.28 | $-0.28 | $-0.26 | $-0.25 | $-0.23 | $-0.10 | $-141.93 | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | ||||
| Common Stock Shares Outstanding | 60.6M | 60.6M | 60.6M | 60.1M | 60.1M | 60.1M | 57.9M | 41.0M | 41.0M | 40.5M | 40.5M | 40.5M | 40.5M | 556.6K | |||
| Common Stock Shares Issued | 60.6M | 60.6M | 60.6M | 60.1M | 60.1M | 60.1M | 57.9M | 41.0M | 41.0M | 40.5M | 40.5M | 40.5M | 40.5M | 556.6K | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $9.9M | $9.6M | $6.1M | $3.1M | $922.0K | $154.0K |
| Additional Paid In Capital | $516.8M | $507.0M | $489.5M | $359.9M | $353.0M | $8.4M |
| Depreciation | $58.0K | $63.0K | $61.0K | $32.0K | $4.0K | |
| Investment Income Interest | $7.4M | $14.3M | $10.8M | |||
| Stock Issued During Period Value Stock Options Exercised | $39.0K | $325.0K | $115.0K | $15.0K | ||
| Embedded Derivative Gain Loss On Embedded Derivative Net | -$460.0K | $1.6M | -$1.4M | $0.00 | ||
| Interest Paid Net | $2.9M | $3.0M | $169.0K | $0.00 | $0.00 | $0.00 |
| Stock Issued During Period Value New Issues | $7.9M | $121.9M | $3.8M | $168.6M | ||
| Other Noncash Expense Interest | $1.3M | $1.1M | $145.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.5M | $2.5M | $2.5M | $2.3M | $2.5M | $2.5M | $1.6M | $1.5M | $1.4M | $840.0K | $715.0K | $618.0K | $304.0K | $127.0K | $126.0K | $39.0K | $38.0K |
| Additional Paid In Capital | $514.4M | $511.9M | $509.4M | $504.7M | $502.3M | $499.8M | $487.1M | $362.9M | $361.3M | $355.2M | $354.3M | $353.6M | $352.6M | $9.2M | |||
| Depreciation | $15.0K | $16.0K | $14.0K | $4.0K | |||||||||||||
| Investment Income Interest | $1.6M | $2.0M | $2.5M | $3.5M | $3.8M | $4.0M | $3.1M | $1.9M | $37.0K | $4.0K | |||||||
| Stock Issued During Period Value Stock Options Exercised | $37.0K | $325.0K | $2.0K | $17.0K | $2.0K | ||||||||||||
| Embedded Derivative Gain Loss On Embedded Derivative Net | -$440.0K | -$40.0K | $190.0K | -$10.0K | $1.1M | -$50.0K | $0.00 | $0.00 | $0.00 | ||||||||
| Interest Paid Net | $724.0K | $756.0K | $0.00 | ||||||||||||||
| Stock Issued During Period Value New Issues | $7.9M | $122.3M | $168.6M | ||||||||||||||
| Other Noncash Expense Interest | $299.0K | $268.0K | $0.00 |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.